182 related articles for article (PubMed ID: 11536307)
1. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Prostate; 2001 Sep; 48(4):274-84. PubMed ID: 11536307
[TBL] [Abstract][Full Text] [Related]
2. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
4. Codistribution of procathepsin B and mature cathepsin B forms in human prostate tumors detected by confocal and immunofluorescence microscopy.
Sinha AA; Quast BJ; Wilson MJ; Reddy PK; Gleason DF; Sloane BF
Anat Rec; 1998 Oct; 252(2):281-9. PubMed ID: 9776083
[TBL] [Abstract][Full Text] [Related]
5. Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis.
Sinha AA; Jamuar MP; Wilson MJ; Rozhin J; Sloane BF
Prostate; 2001 Nov; 49(3):172-84. PubMed ID: 11746262
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of cathepsin B and stefin A expression in Gleason pattern 3+3 (score 6) prostate cancer needle biopsies.
Sinha AA; Morgan JL; Wood N; Betre K; Reddy A; Wilson MJ; Ramanani DM
Anticancer Res; 2007; 27(3B):1407-13. PubMed ID: 17595755
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients.
Sinha AA; Morgan JL; Buus RJ; Ewing SL; Fernandes ET; Le C; Wilson MJ
Anticancer Res; 2007; 27(5A):3135-41. PubMed ID: 17970054
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical study.
Sinha AA; Morgan JL; Betre K; Wilson MJ; Le C; Marks LS
Anticancer Res; 2008; 28(4B):2271-7. PubMed ID: 18751406
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical localization of cathepsin B in neoplastic human prostate.
Sinha AA; Wilson MJ; Gleason DF; Reddy PK; Sameni M; Sloane BF
Prostate; 1995 Apr; 26(4):171-8. PubMed ID: 7716081
[TBL] [Abstract][Full Text] [Related]
11. Characterization of prostate cancer in needle biopsy by cathepsin B, cell proliferation and DNA ploidy.
Qian J; Bostwick DG; Iczkowski KA; Betre K; Wilson MJ; LE C; Sinha AA
Anticancer Res; 2010 Mar; 30(3):719-25. PubMed ID: 20392989
[TBL] [Abstract][Full Text] [Related]
12. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.
Elabbady AA; Khedr MM
Int Urol Nephrol; 2006; 38(3-4):553-7. PubMed ID: 17171424
[TBL] [Abstract][Full Text] [Related]
15. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
16. Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization.
Sinha AA; Gleason DF; Deleon OF; Wilson MJ; Sloane BF
Anat Rec; 1993 Feb; 235(2):233-40. PubMed ID: 7678371
[TBL] [Abstract][Full Text] [Related]
17. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer.
Krepela E; Procházka J; Kárová B; Cermák J; Roubková H
Neoplasma; 1998; 45(5):318-31. PubMed ID: 9921922
[TBL] [Abstract][Full Text] [Related]
18. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
19. Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy.
Calkins CC; Sameni M; Koblinski J; Sloane BF; Moin K
J Histochem Cytochem; 1998 Jun; 46(6):745-51. PubMed ID: 9603786
[TBL] [Abstract][Full Text] [Related]
20. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
